Licensees in the News
-
HIT Fund Teams Make the Leap to Market
From Stanford OTL's Annual Report for Fiscal Year 2025: "Qubits to Clinic"
June 11, 2026
-
This Prickly Patch Could Deliver Vaccines, Take Samples, and More
From Stanford OTL's Annual Report for Fiscal Year 2025: "Qubits to Clinic"
June 11, 2026
-
Stanford-Discovered Molecule Could Underpin New Weight Loss Drugs
From Stanford OTL's Annual Report for Fiscal Year 2025: "Qubits to Clinic"
June 11, 2026
-
Stanford Startup Feon Energy Pursues Better Battery Electrolytes
From Stanford OTL's Annual Report for Fiscal Year 2025: "Qubits to Clinic"
June 11, 2026
-
November 13, 2025
-
July 09, 2025
-
Stanford Licensee Abeona Therapeutics receives U.S. FDA Approval for ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure.
April 29, 2025
-
Stanford Licensee Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
Epic Bio is a biotechnology company focused on developing curative therapies.
April 03, 2025
-
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
Vera Therapeutics has announced an exclusive license agreement with Stanford University.
January 13, 2025
-
Stanford Licensee Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting
Synthekine Inc., which was founded on tech licensed from K. Christopher Garcia’s Stanford lab, today announced positive initial results from a first-in-human Phase 1 study.
December 09, 2024
-
BridgeBio's Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Acoramidis is based on a Stanford technology licensed by Eidos Therapeutics, which BridgeBio acquired in 2021.
November 22, 2024
-
Stanford Licensee Valora Therapeutics Raises $30 Million Seed Financing from Top Investors to Transform Immunotherapy with a Novel Glyco-immune Checkpoint Platform
Valora, a biotech company pioneering a novel approach to immunotherapy, today announced the successful closing of its seed funding round.
November 20, 2024
-
Stanford Licensee Lightmatter Raises $400M Series D; Quadruples Valuation to $4.4B as Photonics Leader for Next-Gen AI Data Centers
Amid unprecedented demand for extreme-scale data centers, Lightmatter prepares for next phase of growth.
October 16, 2024
-
Metabolize, a startup founded on technology licensed from Stanford, Unveils Groundbreaking Weight Reduction Metabolite, with Breakthrough Findings Published in Nature
The newly published research highlights N-acetyltaurine's (NAT) potential for significant weight loss through appetite suppression.
September 10, 2024
-
Metabolize Licenses Two Proprietary Metabolites to Address Obesity from Stanford OTL
The licensing agreement is for two promising metabolites with the potential to significantly improve metabolic health and naturally address the obesity epidemic.
July 30, 2024
-
Magnus Medical Receives FDA Clearance for the SAINT Neuromodulation System for Non-Invasive, Individualized and Precise Treatment of Severe Depression
Magnus Medical Receives FDA Clearance for the SAINT Neuromodulation System for Non-Invasive, Individualized and Precise Treatment of Severe Depression
September 22, 2022
-
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions
Research collaborations initiated with MUSC Foundation for Research Development, SU and the U of Pittsburgh to identify and advance therapies for genetic diseases and cancers.
July 08, 2021
-
June 24, 2021
-
Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
Total of $195 million raised to date. | The financing, led by RA Capital Management and Rock Springs Capital, included participation by other prominent new and existing investors.
March 15, 2021
-
Graphite Bio Receives IND Clearance to Initiate Clinical Trial for Next-Generation Gene Editing Therapy GPH101 in Sickle Cell Disease
IND clearance for Phase 1/2 trial establishes Graphite Bio as the first company advancing potentially curative sickle cell gene therapy to restore normal hemoglobin expression
December 14, 2020
